Emfizatamab clinical trials
Also written GNC-038.
How each study uses emfizatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the emfizatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GNC-038
- 7
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test emfizatamab.
- Dec 2026A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses emfizatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05623982Written as GNC-038
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT06857214Written as GNC-038
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid ArthritisRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT06857227Written as GNC-038
- A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05192486Written as GNC-038
- A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Active, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05485753Written as GNC-038
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05627856Written as GNC-038
- Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaActive, not recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT04606433Written as GNC-038
Codes
What other systems call emfizatamab · ClinicalTrials.gg INT016545
- UNII (FDA) FB8PCJ9N3HEMFIZATAMABOne source FDA
- NCI Thesaurus C178448EmfizatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FB8PCJ9N3H | EMFIZATAMAB | One source FDA |
| NCI Thesaurus | C178448 | Emfizatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.